Chen Fangjun, Yeung Priscilla S-W, Wong Carolyn V, Luo Ruben Y
Department of Pathology, Stanford University, Stanford, CA, USA.
Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA.
J Mass Spectrom Adv Clin Lab. 2025 Jan 31;35:8-13. doi: 10.1016/j.jmsacl.2025.01.001. eCollection 2025 Jan.
N-terminal carbamylated hemoglobin (CarHb) reflects long-term blood urea levels and has potential as a marker for chronic kidney disease (CKD) and other chronic conditions with elevated blood urea levels. A liquid chromatography-high-resolution mass spectrometry (LC-HR-MS) method was developed to measure CarHb.
Apparent CarHb/Hb ratios were calculated from the peak area ratios of carbamylated to native N-terminal peptides digested from hemoglobin alpha and beta subunits. Blood samples from healthy individuals, CKD patients, and chronic obstructive pulmonary disease (COPD) patients were analyzed.
The apparent CarHb/Hb ratios were significantly higher in CKD and COPD patients compared to healthy individuals. However, no significant differences were observed between the CKD and COPD patient groups.
In this study, an LC-HR-MS method was developed for quantifying the apparent CarHb/Hb ratios and exploring their potential for clinical diagnostic applications. CarHb is a promising marker for monitoring kidney diseases and other chronic conditions with elevated blood urea levels. Beyond CarHb, the use of other carbamylated proteins as clinical diagnostic and prognostic markers can be explored.
N 端氨甲酰化血红蛋白（CarHb）反映长期血尿素水平，有潜力作为慢性肾脏病（CKD）及其他血尿素水平升高的慢性疾病的标志物。已开发出一种液相色谱-高分辨率质谱（LC-HR-MS）方法来测定 CarHb。
从血红蛋白α和β亚基消化产生的氨甲酰化与天然 N 端肽的峰面积比计算表观 CarHb/Hb 比值。对健康个体、CKD 患者和慢性阻塞性肺疾病（COPD）患者的血样进行分析。
与健康个体相比，CKD 和 COPD 患者的表观 CarHb/Hb 比值显著更高。然而，CKD 和 COPD 患者组之间未观察到显著差异。
在本研究中，开发了一种 LC-HR-MS 方法用于定量表观 CarHb/Hb 比值并探索其临床诊断应用潜力。CarHb 是监测肾脏病和其他血尿素水平升高的慢性疾病的有前景的标志物。除 CarHb 外，还可探索使用其他氨甲酰化蛋白作为临床诊断和预后标志物。
